Psyence Biomedical (PBM) announced the recruitment of Perth, Australia-based Empax Center as the second trial site for Psyence’s Biomed ongoing Phase IIb clinical trial of nature-derived psilocybin as a potential treatment for Adjustment Disorder in Palliative Care. Psyence Biomed on track to begin recruitment this quarter, and to announce Adjustment Disorder topline data in the second half of 2025
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PBM:
- Psyence Biomedical Plans Key Shareholder Meeting
- Psyence Biomedical provides update on PsyLabs E.U. GMP certified API development
- Psyence Biomedical Converts Debt to Equity
- Psyence Biomedical will not proceed with Clairvoyant Therapeutics acquisition
- Psyence Biomedical files to sell 10.9M common shares for holders